| Biotechnology Industry | Healthcare Sector | Gregory T. Mayes CEO | NASDAQ (NGS) Exchange | 76134G103 CUSIP |
| CA Country | 16 Employees | - Last Dividend | 17 Aug 2022 Last Split | - IPO Date |
Field Trip Health & Wellness Ltd. is a pioneering healthcare company that specializes in offering psychedelic therapies. With its operations spanning across North America and Europe, the company has positioned itself at the forefront of integrating psychedelic substances into therapeutic practices. Based in Toronto, Canada, Field Trip Health & Wellness has embarked on a mission to harness the potential of psychedelics in treating a variety of mental health conditions, thereby contributing to the broader acceptance and understanding of these substances in medicinal contexts.
At the core of Field Trip Health & Wellness Ltd.'s offerings are its psychedelic therapies. These involve the controlled use of psychedelic substances, such as psilocybin, in a therapeutic setting to address mental health issues like depression, anxiety, and PTSD. The therapies are conducted under the guidance of trained professionals, ensuring safety and effectiveness in treatment.
The company operates a network of health centers located in North America and Europe. These centers are the physical spaces where the psychedelic therapies are administered. Designed to provide a secure, comfortable, and supportive environment, these centers play a crucial role in the therapeutic process, influencing the overall treatment experience and outcomes.